Advertisement
Table 2 Clinical and laboratory data of patients with liver cirrhosis and hepatocellular carcinoma
| Characteristics | LC | HCC | P |
|---|---|---|---|
| AFP (ng/mL) | 6.2 ± 15.8 | 507.8 ± 1565.9 | < 0.001* |
| AFP ≥ 20 ng/mL | 2 (6.67) | 12 (37.5) | - |
| AFP ≥ 200 ng/mL | 0 (0.0) | 6 (18.8) | - |
| ALT (UI/mL) | 35.4 ± 41.3 | 39.5 ± 43.2 | 0.698 |
| AST (UI/mL) | 37.3 ± 22.4 | 45.3 ± 43.0 | 0.746 |
| ALP (U/L) | 86.6 ± 51.6 | 119.2 ± 70.1 | 0.022* |
| GGT (U/L) | 64.2 ± 98.2 | 108.1 ± 121.0 | 0.045* |
| Total bilirubin (mg/dL) | 0.7 ± 0.3 | 1.1 ± 1.4 | 0.481 |
| Albumin (g/dL) | 4.7 ± 0.4 | 4.4 ± 0.8 | 0.117 |
| Platelets (*1,000/mm3) | 155.8 ± 89.5 | 156.0 ± 86.3 | 0.910 |
| PT (seconds) | 14.1 ± 2.1 | 13.2 ± 1.7 | 0.013* |
| Child-Pugh score | |||
| A | 30 (53.6) | 26 (46.4) | 0.030* |
| B or C | 0 (0.0) | 6 (100.0) | |
| Total cholesterol (mg/dL) | 179.4 ± 38.1 | 172.8 ± 41.0 | 0.511 |
| Tumor size (mm) | - | 37.0 ± 23.0 | - |
| BCLC stage | |||
| 0 | - | 5 (15.6) | - |
| A | - | 14 (43.8) | - |
| B | - | 10 (31.2) | - |
| C | - | 1 (3.1) | - |
| D | - | 2 (6.3) | - |
